肌萎缩性脊髓侧索硬化症患者生存的肺功能预测因素:用于临床试验设计

Pulmonary predictors of survival in amyotrophic lateral sclerosis:Use in clinical trial design

The rapidity of progression of amyotrophic lateral sclerosis (ALS) to death or respiratory failure impacts patients, clinicians, and clinical investigators. This study compared the abilities of various pulmonary function tests to predict tracheostomy-free survival. We evaluated 95 ALS patients by determining upright and supine forced vital capacity (FVC), maximal inspiratory (MIP) and expiratory (MEP) pressures, arterial partial pressure of carbon dioxide (PaCO2), and tran sdiaphragmatic sniff pressures (Pdi-sniff). Tracheostomy-free survival time was measured from the date of spirometry. Supine FVC, upright FVC,MIP,MEP, and Pdi-sniff were significantly associated with tracheostomy-free survival after controlling for non-pulmonary factors, whereas PaCO2 was not. A normal supine FVC, MIP, or MEP was highly predictive for one-year survival. These tests are well suited to predict survival for trial enrollment and patient counseling. Supine FVC’s simplicity of use and availability to ALS investigators makes it a particularly attractive predictor of one-year survival in ALS.

The rapidity of progression of amyotrophic lateral sclerosis （ALS） to death or respiratory failure impacts patients, clinicians, and clinical investigators. This study compared the abilities of various pulmonary function tests to predict tracheostomy-free survival. We evaluated 95 ALS patients by determining upright and supine forced vital capacity （FVC）, maximal inspiratory （MIP） and expiratory （MEP） pressures, （PaCO2）, （Pdi-sniff） arterial partial pressure of carbon dioxide and transdiaphragmatic sniff pressures . Tracheostomy-free survival time was measured from the date of spirometry. Supine FVC, upright FVC, MIP, MEP, and Pdi-sniff were significantly associated with tracheostomy-free survival after controlling for non-pulmonary factors, whereas PaCO2 was not. A normal supine FVC, MIP, or MEP was highly predictive for one-year survival. These tests are well suited to predict survival for trial enrollment and patient counseling. Supine FVC＇ s simplicity of use and availability to ALS investigators makes it a particularly attractive predictor of one-year survival in ALS.